sponse rate of 55% to 70%. 2 Extraintestinal manifestations associated with IBD are seen in 21% to 41% of patients with IBD.
INTRODUCTION
Oral 5-aminosalicylic acid (5-ASA) agents such as mesalazine and sulfasalazine are the mainstay of treatment for mild to moderate IBD. Although sulfasalazine is an effective treatment for IBD, up to 30% of patients experience adverse effects such as nausea, vomiting, abdominal discomfort, diarrhea, headache, pancreatitis, agranulocytosis, and pulmonary toxicity. The newer sulfa-free 5-ASA agent, mesalazine, delivers increased amounts of the active compound while limiting the adverse effects mostly caused by sulfapyridine. 1 Azathioprine (AZA) is widely used in the treatment of IBD; this drug can induce and maintain remission with a re-www.irjournal.org wide. Domestic reports of drug-induced pulmonary toxicity in patients with IBD include 1 case of eosinophilic pneumonia and 1 case of interstitial pneumonia. Only 2 cases of eosinophilic pneumonia due to mesalazine have been reported in patients with CD. Only 3 cases of AZA-induced eosinophilic pneumonia have been reported worldwide. We, herein, describe a patient with CD who developed the rare complication of eosinophilic pneumonia during mesalazine and AZA treatment. The patient' s disease activity and treatment effectiveness were evaluated with FENO.
CASE REPORT
A 26-year-old man with a 3-week history of coughing presented to Gachon University Gil Medical Center. He had been diagnosed with iron deficiency anemia 2 years previously. Ten months previously, he underwent small bowel resection and anastomosis for treatment of a small bowel perforation and was diagnosed with CD based on the biopsy findings (inflammation and noncaseating granuloma formation on the bowel wall) (Fig. 1) .
The patient was a lifelong nonsmoker and nondrinker and had not recently traveled to any foreign countries. He had no significant family medical history. After the diagnosis of CD, he was treated with mesalazine at 3 g/day for 10 months. During the first week after the diagnosis, he had received prednisolone at 30 mg/day; this dose was tapered and discontinued. He developed tenesmus and hematochezia after 6 months of treatment with mesalazine, and prednisolone was restarted at 15 mg/day and the dose was tapered for 3 weeks. Four weeks before his visit to our hospital, the hematochezia reappeared along with abdominal pain and an elevated CRP level. Because of disease exacerbation, 50 mg of AZA was added until the day of hospital admission.
The patient' s abdominal pain had subsided at the time of hospital admission, but he exhibited dry coughing with white sputum, dyspnea, and chest discomfort. He had no chills or fever. His blood pressure was 110/70 mmHg, pulse was 106/ min, body temperature was 36. (Fig. 2) . Chest CT showed subpleural consolidation and groundglass opacities in the bilateral lung fields (Fig. 3A) . Similar findings were present on small bowel CT performed 3 weeks before admission (1 week into AZA treatment); however, these findings were more severe. Because of signs of atypical pneumonia and elevated eosinophil count of 519.5/mm 3 , the possibility of eosinophilic pneumonia was considered, and mesalazine and AZA were discontinued. Findings of sputum AFB smear, fungal smear, Mesalazine was continued for 10 months. A chest radiograph after 1 week of AZA treatment showed a reticulonodular density and peripheral blood tests showed increased eosinophils; BAL also showed increased eosinophils (14%). Based on these results, the patient was diagnosed with mesalazine-or AZA-associated eosinophilic pneumonia. After discontinuation of mesalazine and AZA and 2 weeks of treatment with prednisolone at 30 mg/day, all pulmonary symptoms of the patient resolved; follow-up chest CT after 5 days also showed improvement (Fig. 3B ). Blood test results during outpatient visits showed decreased eosinophil levels (as low as 3.2%) and a decreased posttreatment FENO level (13 ppb) on BAL; chest radiographs no longer showed signs of pulmonary abnormalities. The patient's CD stabilized even after the discontinuation of mesalazine, and the eosinophilic pneumonia did not recur. 
DISCUSSION
Our patient had a 1-year history of CD, and his pulmonary symptoms occurred 10 months after the initial administration of mesalazine and after 1 week of AZA treatment. Multifocal subpleural consolidations and ground-glass opacities in both the left and right basal lung fields were present on the initial chest radiograph and chest CT. BAL was performed for a definitive diagnosis. Eosinophilia was detected in the patient' s peripheral blood (7.4%) and BAL fluid (14.0%). His clinical signs and radiologic findings improved after discontinuation of mesalazine and AZA and the 2-week steroid treatment. The FENO was 74 ppb on BAL at diagnosis, decreasing to 13 ppb after treatment.
The inflammatory status of acute eosinophilic pneumonia (AEP) may be reflected in the FENO level, which has been shown to be higher in patients with than in those without AEP. In addition, the FENO level has been shown to decrease with steroid treatment. 5 Because our patient's sputum AFB smear test, fungal smear test, bacterial culture, cytology, QuantiFERON Gold test, and virology test results were all negative, we excluded infectious disease and a diagnosis of mesalazine-or AZA-induced eosinophilic pneumonia was made. His pulmonary symptoms resolved after treatment with prednisolone at 30 mg/day for 2 weeks, and follow-up chest CT 5 days later showed improvement. Blood test results from his outpatient visits showed decreased eosinophil levels, and chest radiographs no longer showed signs of pulmonary abnormalities. A drug lymphocyte stimulation test and re-challenge were performed to confirm the presence of drug-induced eosinophilic pneumonia. However, we did not perform a mesalazine or AZA lymphocyte stimulation test because the patient' s condition may have become aggravated. If mesalazine or AZA is inevitably needed to treat IBD, oral desensitization to 5-ASA should be performed. 6 These reactions can also be overcome by desensitization of the immune system to the drug. 7 AEP is a distinct pneumonia syndrome. The etiology and pathophysiology of AEP are unclear; however, AEP is often associated with drug treatment. 8 Sulfasalazine (sulfapyridine bound to 5-ASA) and mesalazine (5-ASA alone) are treatment options for patients with variations of IBD such as CD and UC. 1 AZA, a purine analog, induces and maintains remission in IBD. 9 The detailed mechanisms of sulfasalazine action remain unknown, potential mechanisms include scavenging of free radicals, inhibition of nuclear factor κB, induction of apoptosis, and interference with arachidonic acid metabolism. 4, 10 Sulfasalazine is metabolized to sulfapyridine and 5-ASA. Adverse effects of sulfasalazine include nausea, gastric discomfort, headache, anorexia, skin rashes, male infertility, and pulmonary syndromes during IBD treatment. These adverse effects of sulfasalazine are caused by its sulfamic vector, not by 5-ASA or mesalazine. 11 5-ASA clinically decreases inflammation of the colon and rectum. In this regard, mesalazine has been widely used for IBD treatment. Possible mechanisms of action of mesalazine include the inhibition of interleukin-1, tumor necrosis factor-α, and nuclear factor κB. However, the pathogenesis of mesalazine-related pulmonary involvement remains unclear. Four proposed mechanisms are oxidative injury by drugs such as nitrofurantoin, direct cytotoxic effect on alveolar capillary endothelial cells, cell-mediated injury secondary to deposition of phospholipids, and immunemediated injury resulting in clinical symptoms of systemic lupus erythematosus. Immune-related alveolitis secondary to lymphocyte stimulation is currently being considered a possible mechanism of mesalazine-related pulmonary involvement. 1, 4, 12 AZA is a purine analog inhibiting the synthesis of purine nucleotide. The pathogenesis of AZA is not well understood. There are 2 alternative pathways; one to 6-thiouric acid mediated by xanthine oxidase and the other to 6-methylmercaptopurine mediated by thiopurine methyltransferase. 13 AZA is frequently associated with a number of adverse effects, and it is usually discontinued due to the adverse effects. There are 2 types of adverse effects: (1) the allergic type including pancreatitis, fever, rash, malaise, nausea, diarrhea, and hepatitis, and the (2) the nonallergic type including leucopenia and some forms of hepatitis. 14 The pulmonary adverse effects of mesalazine and AZA include fever, fatigue, dyspnea, chest pain, and coughing. 15 The adverse effects of mesalazine appear 1 to 6 months after treatment. The adverse effects of AZA appear within 1 month after treatment. If interstitial infiltration with a ground-glass pattern and pulmonary nodules are present on a chest radiograph or CT scan, peripheral eosinophilia may be detected on laboratory tests. BAL fluid may show elevated eosinophil and lymphocyte counts and a decreased CD4/CD8 ratio. Pulmonary function tests usually reveal a reduced diffusion capacity for carbon monoxide. Histological findings include eosinophilic infiltration of the alveoli, lymphocytic infiltration of the interstitium, and nonnecrotizing granulomas. 12 It is not easy to distinguish drug-related pulmonary involvement from pulmonary manifestations of IBD. Mesalazine affects the lung parenchyma, while IBD affects the large airways of the lung. 16, 17 Mesalazine-induced lung disease includes eosinophilic pneumonia and fibrosing alveolitis. AZA can lead to opportunistic infections. To date, 38 cases (39 patients) of mesalazine-related pulmonary involvement have been reported worldwide. Among them, eosinophilic pneumonia was the most common presentation.
3 Thirty-three patients had UC (84.6%), and 6 patients had CD (15.4%). At the time of symptom development, the mean age of mesalazine-related pulmonary involvement was 42 years. The relationship between the dose of mesalazine and the lung toxicity was unclear. The dose of mesalazine varied from 750 mg/day to 4800 mg/day. The interval between the start of mesalazine treatment and the expression of pulmonary symptoms varied from 2 days to 4-5 years. In total, 38 patients stopped mesalazine, and 23 of them (60.5%) were treated with systemic glucocorticoids. Interstitial lung infiltration was the most common radiologic finding (73.0% of patients). Seven patients underwent a rechallenge, and 4 (57.1%) developed recurrent pulmonary involvement. 18 AZA-induced pulmonary toxicity has rarely been reported in patients with IBD. AZA-related pulmonary toxicity was first reported by Rubin et al. 19 in 1972, with the report describing a CD patient with exertional dyspnea. Krowka et al. 20 in 1983 reported in a 35-year-old man with intermittent fever. AZA-related pulmonary toxicity was mostly reported in patients with renal allograft transplantation. In IBD patients, AZA-related pulmonary toxicity has rarely been reported. 14 The present study had 2 main limitations. First, we were unable to elucidate the mechanism of the mesalazine-or AZA-induced eosinophilic pneumonia. Second, re-challenge with mesalazine and AZA was not performed because the patient did not have symptoms of IBD. Mesalazine-induced eosinophilic pneumonia usually occurs after 2 to 6 months of treatment. In some case reports, this varied from a few days to years after treatment. AZA induced pulmonary toxicity occurs within 1 month after initiation of treatment for IBD. In IBD patients, AZA-induced eosinophilic pneumonia has rarely been reported. Our patient had a 1-year history of CD, and his pulmonary symptoms occurred 10 months after the initial administration of mesalazine and only after 1 week of AZA treatment. In this regard, the AZA was more likely related to the eosinophilic pneumonia than to mesalamine, considering the time interval between drugs. Ideally, AZA re-challenge would be a definitive diagnostic tool. However, this seemed unethical because the patient has no symptoms to date.
Despite these limitations, this is the first report of eosinophilic pneumonia in a patient treated with mesalazine and AZA for CD. We also found that the FENO level was elevated in this patient with drug-induced eosinophilic pneumonia. After treatment of the drug-induced eosinophilic pneumonia, the FENO level decreased and the symptoms improved. In this regard, the FENO level might be related to the disease activity and treatment effectiveness of drug-induced eosinophilic pneumonia.
In conclusion, we have described a 26-year-old man who was diagnosed with eosinophilic pneumonia after treatment with mesalazine and AZA for CD and who recovered after treatment. Additionally, the present study shows that the FENO is related to disease activity and treatment effectiveness of drug-induced eosinophilic pneumonia.
